BiVictriX26 May 2021 18:31
Just looking over the BiVictriX website and it seems that they are trying to do the same type of thing as another company I am in, Avacta.
Avacta are just about to start phase 1 trials in AVA6000 which is a precision activated chemotherapy so the chemo is only active in a tumour and so does not have the negative effects on the rest of the body. Avacta are targeting locally advanced or metastatic solid tumours, which are known to be FAP positive including pancreatic, colorectal, breast, ovarian, bladder and non-small cell lung cancers, squamous cell carcinoma of the head and neck and soft-tissue sarcoma.
So BiVictriX are targeting Acute Myeloid leukaemia and Avacta are targeting solid tumour type cancers but if these company's can succeed in what they have set out to do then they would be multi, multi billion pound company's. Who knows, maybe in the future they could work together!